Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program
Abstract Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach t...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-06-01
|
| Series: | Schizophrenia |
| Online Access: | https://doi.org/10.1038/s41537-025-00599-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850224242310774784 |
|---|---|
| author | Johanna T. W. Wigman Ann Ee Ching Yoonho Chung Habiballah Rahimi Eichi Erlend Lane Carsten Langholm Aditya Vaidyam Andrew Jin Soo Byun Anastasia Haidar Jessica Hartmann Angela Nunez Dominic Dwyer Adibah Amani Nasarudin Owen Borders Isabelle Scott Zailyn Tamayo Priya Matneja Kang-Ik Cho Jean Addington Luis K. Alameda Celso Arango Nicholas J. K. Breitborde Matthew R. Broome Kristin S. Cadenhead Monica E. Calkins Eric Yu Hai Chen Jimmy Choi Philippe Conus Cheryl M. Corcoran Barbara A. Cornblatt Covadonga M. Diaz-Caneja Lauren M. Ellman Paolo Fusar-Poli Pablo A. Gaspar Carla Gerber Louise Birkedal Glenthøj Leslie E. Horton Christy Lai Ming Hui Joseph Kambeitz Lana Kambeitz-Ilankovic Matcheri S. Keshavan Sung-Wan Kim Nikolaos Koutsouleris Kerstin Langbein Daniel Mamah Daniel H. Mathalon Vijay A. Mittal Merete Nordentoft Godfrey D. Pearlson Jesus Perez Diana O. Perkins Albert R. Powers Jack Rogers Fred W. Sabb Jason Schiffman Jai L. Shah Steven M. Silverstein Stefan Smesny Walid Yassin William S. Stone Gregory P. Strauss Judy L. Thompson Rachel Upthegrove Swapna Verma Jijun Wang Daniel H. Wolf Phillip Wolff Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Laura M. Rowland Simon D’Alfonso Ofer Pasternak Sylvain Bouix Patrick D. McGorry Rene S. Kahn John M. Kane Carrie E. Bearden Scott W. Woods Martha E. Shenton Barnaby Nelson Justin T. Baker John Torous |
| author_facet | Johanna T. W. Wigman Ann Ee Ching Yoonho Chung Habiballah Rahimi Eichi Erlend Lane Carsten Langholm Aditya Vaidyam Andrew Jin Soo Byun Anastasia Haidar Jessica Hartmann Angela Nunez Dominic Dwyer Adibah Amani Nasarudin Owen Borders Isabelle Scott Zailyn Tamayo Priya Matneja Kang-Ik Cho Jean Addington Luis K. Alameda Celso Arango Nicholas J. K. Breitborde Matthew R. Broome Kristin S. Cadenhead Monica E. Calkins Eric Yu Hai Chen Jimmy Choi Philippe Conus Cheryl M. Corcoran Barbara A. Cornblatt Covadonga M. Diaz-Caneja Lauren M. Ellman Paolo Fusar-Poli Pablo A. Gaspar Carla Gerber Louise Birkedal Glenthøj Leslie E. Horton Christy Lai Ming Hui Joseph Kambeitz Lana Kambeitz-Ilankovic Matcheri S. Keshavan Sung-Wan Kim Nikolaos Koutsouleris Kerstin Langbein Daniel Mamah Daniel H. Mathalon Vijay A. Mittal Merete Nordentoft Godfrey D. Pearlson Jesus Perez Diana O. Perkins Albert R. Powers Jack Rogers Fred W. Sabb Jason Schiffman Jai L. Shah Steven M. Silverstein Stefan Smesny Walid Yassin William S. Stone Gregory P. Strauss Judy L. Thompson Rachel Upthegrove Swapna Verma Jijun Wang Daniel H. Wolf Phillip Wolff Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Laura M. Rowland Simon D’Alfonso Ofer Pasternak Sylvain Bouix Patrick D. McGorry Rene S. Kahn John M. Kane Carrie E. Bearden Scott W. Woods Martha E. Shenton Barnaby Nelson Justin T. Baker John Torous |
| author_sort | Johanna T. W. Wigman |
| collection | DOAJ |
| description | Abstract Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach to explore the nature of CHR and may help to improve personalized risk prediction. Specifically, digital data enable detailed mapping of experiences, moods and behaviors during longer periods of time (e.g., weeks, months) and offer more insight into patterns over time at the individual level across their routine daily life. However, while novel digital health technologies open up many new avenues of research, they also come with specific challenges, including replicability of results and the adherence of participants. This paper outlines the design of the digital component of the Accelerating Medicines Partnership® Schizophrenia Program (AMP SCZ) project, a large international collaborative project that follows individuals at CHR for psychosis over a period of two years. The digital component comprises one-year smartphone-based digital phenotyping and actigraphy. Smartphone-based digital phenotyping includes 30-item short daily self-report surveys and voice diaries as well as passive data capture (geolocation, on/off screen state, and accelerometer). Actigraphy data are collected via an Axivity wristwatch. The aim of this paper is to describe the design and the three goals of the digital measures used in AMP SCZ to: (i) better understand the symptoms, real-life experiences, and behaviors of those at CHR for psychosis, (ii) improve the prediction of transition to psychosis and other health outcomes in this population based on digital phenotyping and, (iii) serve as an example for replicable and ethical research across geographically diverse regions and cultures. Accordingly, we describe the rationale, protocol and implementation of these digital components of the AMP SCZ project. **Link to video interview: https://vimeo.com/1060935583 ** |
| format | Article |
| id | doaj-art-47cc7cf97af44f929e85ef9ca6fa098d |
| institution | OA Journals |
| issn | 2754-6993 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Schizophrenia |
| spelling | doaj-art-47cc7cf97af44f929e85ef9ca6fa098d2025-08-20T02:05:41ZengNature PortfolioSchizophrenia2754-69932025-06-0111111010.1038/s41537-025-00599-wDigital health technologies in the accelerating medicines Partnership® Schizophrenia ProgramJohanna T. W. Wigman0Ann Ee Ching1Yoonho Chung2Habiballah Rahimi Eichi3Erlend Lane4Carsten Langholm5Aditya Vaidyam6Andrew Jin Soo Byun7Anastasia Haidar8Jessica Hartmann9Angela Nunez10Dominic Dwyer11Adibah Amani Nasarudin12Owen Borders13Isabelle Scott14Zailyn Tamayo15Priya Matneja16Kang-Ik Cho17Jean Addington18Luis K. Alameda19Celso Arango20Nicholas J. K. Breitborde21Matthew R. Broome22Kristin S. Cadenhead23Monica E. Calkins24Eric Yu Hai Chen25Jimmy Choi26Philippe Conus27Cheryl M. Corcoran28Barbara A. Cornblatt29Covadonga M. Diaz-Caneja30Lauren M. Ellman31Paolo Fusar-Poli32Pablo A. Gaspar33Carla Gerber34Louise Birkedal Glenthøj35Leslie E. Horton36Christy Lai Ming Hui37Joseph Kambeitz38Lana Kambeitz-Ilankovic39Matcheri S. Keshavan40Sung-Wan Kim41Nikolaos Koutsouleris42Kerstin Langbein43Daniel Mamah44Daniel H. Mathalon45Vijay A. Mittal46Merete Nordentoft47Godfrey D. Pearlson48Jesus Perez49Diana O. Perkins50Albert R. Powers51Jack Rogers52Fred W. Sabb53Jason Schiffman54Jai L. Shah55Steven M. Silverstein56Stefan Smesny57Walid Yassin58William S. Stone59Gregory P. Strauss60Judy L. Thompson61Rachel Upthegrove62Swapna Verma63Jijun Wang64Daniel H. Wolf65Phillip Wolff66Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ)Laura M. Rowland67Simon D’Alfonso68Ofer Pasternak69Sylvain Bouix70Patrick D. McGorry71Rene S. Kahn72John M. Kane73Carrie E. Bearden74Scott W. Woods75Martha E. Shenton76Barnaby Nelson77Justin T. Baker78John Torous79University of Groningen, University Medical Center Groningen, Department of Psychiatry, Interdisciplinary Centre of Psychopathology and Emotion regulationCentre for Youth Mental Health, The University of MelbourneMcLean HospitalMcLean HospitalBeth Israel Deaconess Medical Center, Harvard Medical SchoolBeth Israel Deaconess Medical Center, Harvard Medical SchoolBeth Israel Deaconess Medical Center, Harvard Medical SchoolBeth Israel Deaconess Medical Center, Harvard Medical SchoolBrigham and Women’s Hospital, Harvard Medical SchoolOrygenYale UniversityCentre for Youth Mental Health, The University of MelbourneCentre for Youth Mental Health, The University of MelbourneBrigham and Women’s Hospital, Harvard Medical SchoolCentre for Youth Mental Health, The University of MelbourneYale UniversityNorthwell HealthHarvard Medical SchoolDepartment of Psychiatry, Hotchkiss Brain Institute, University of CalgaryService de Psychiatrie Générale Dép. de Psychiatrie CHUV LausanneDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CIBERSAM, ISCIII, School of Medicine, Universidad ComplutenseDepartment of Psychiatry and Behavioral Health, Ohio State UniversityInstitute for Mental Health, School of Psychology, University of BirminghamUniversity of CaliforniaDepartment of Psychiatry, Perelman School of Medicine, University of PennsylvaniaDepartment of Psychiatry, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong KongOlin Neuropsychiatry Research Center, Hartford HealthCare Behavioral Health NetworkService de Psychiatrie Générale Dép. de Psychiatrie CHUV LausanneDepartment of Psychiatry, Icahn School of Medicine at Mount SinaiDepartment of Psychiatry, Donald and Barbara Zucker School of MedicineDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CIBERSAM, ISCIII, School of Medicine, Universidad ComplutenseDepartment of Psychology & Neuroscience, Temple UniversityDepartment of Psychosis Studies, King’s College LondonDepartment of Psychiatry, IMHAY, University of ChileBehavioral Health Services, PeaceHealth Medical GroupCopenhagen Research Centre for Mental Health, Mental Health Copenhagen, Department of Psychology, University of CopenhagenDepartment of Psychiatry, University of Pittsburgh School of MedicineDepartment of Psychiatry, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong KongDepartment of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of CologneDepartment of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of CologneHarvard Medical SchoolDepartment of Psychiatry, Chonnam National University Medical SchoolDepartment of Psychosis Studies, King’s College LondonDepartment of Psychiatry and Psychotherapy, Jena University HospitalDepartment of Psychiatry, Washington University School of MedicineDepartment of Psychiatry and Behavioral Sciences and Weill Institute for Neurosciences, University of California, San FranciscoDepartment of Psychology, Northwestern UniversityMental Health Services in the Capital RegionOlin Neuropsychiatry Research Center, Institute of Living, Hartford HospitalMcLean HospitalDepartment of Psychiatry, University of North CarolinaYale UniversityCentre for Human Brain Health, University of BirminghamDepartment of Psychiatry, University of ChileDepartment of Psychological Science, University of CaliforniaPEPP-Montreal, Douglas Research Centre, MontrealDepartment of Psychiatry, University of Rochester Medical CenterDepartment of Psychiatry and Psychotherapy, Jena University HospitalHarvard Medical SchoolHarvard Medical SchoolDepartment of Psychology, University of GeorgiaDepartment of Psychiatry, University of Rochester Medical Center, RochesterInstitute for Mental Health, School of Psychology, University of BirminghamInstitute of Mental HealthShanghai Mental Health Center, Shanghai Jiaotong University School of MedicineDepartment of Psychiatry, Perelman School of Medicine, University of PennsylvaniaDepartment of Psychology, Emory UniversityNational Institute of Mental HealthSchool of Computing and Information Systems, The University of MelbourneBrigham and Women’s Hospital, Harvard Medical SchoolBrigham and Women’s Hospital, Harvard Medical SchoolCentre for Youth Mental Health, The University of MelbourneDepartment of Psychiatry, Icahn School of Medicine at Mount SinaiDepartment of Psychiatry, Donald and Barbara Zucker School of MedicineDepartments of Psychiatry and Biobehavioral Sciences & Psychology, Semel Institute for Neuroscience and Human Behavior, University of CaliforniaYale UniversityHarvard Medical SchoolCentre for Youth Mental Health, The University of MelbourneMcLean HospitalHarvard Medical SchoolAbstract Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach to explore the nature of CHR and may help to improve personalized risk prediction. Specifically, digital data enable detailed mapping of experiences, moods and behaviors during longer periods of time (e.g., weeks, months) and offer more insight into patterns over time at the individual level across their routine daily life. However, while novel digital health technologies open up many new avenues of research, they also come with specific challenges, including replicability of results and the adherence of participants. This paper outlines the design of the digital component of the Accelerating Medicines Partnership® Schizophrenia Program (AMP SCZ) project, a large international collaborative project that follows individuals at CHR for psychosis over a period of two years. The digital component comprises one-year smartphone-based digital phenotyping and actigraphy. Smartphone-based digital phenotyping includes 30-item short daily self-report surveys and voice diaries as well as passive data capture (geolocation, on/off screen state, and accelerometer). Actigraphy data are collected via an Axivity wristwatch. The aim of this paper is to describe the design and the three goals of the digital measures used in AMP SCZ to: (i) better understand the symptoms, real-life experiences, and behaviors of those at CHR for psychosis, (ii) improve the prediction of transition to psychosis and other health outcomes in this population based on digital phenotyping and, (iii) serve as an example for replicable and ethical research across geographically diverse regions and cultures. Accordingly, we describe the rationale, protocol and implementation of these digital components of the AMP SCZ project. **Link to video interview: https://vimeo.com/1060935583 **https://doi.org/10.1038/s41537-025-00599-w |
| spellingShingle | Johanna T. W. Wigman Ann Ee Ching Yoonho Chung Habiballah Rahimi Eichi Erlend Lane Carsten Langholm Aditya Vaidyam Andrew Jin Soo Byun Anastasia Haidar Jessica Hartmann Angela Nunez Dominic Dwyer Adibah Amani Nasarudin Owen Borders Isabelle Scott Zailyn Tamayo Priya Matneja Kang-Ik Cho Jean Addington Luis K. Alameda Celso Arango Nicholas J. K. Breitborde Matthew R. Broome Kristin S. Cadenhead Monica E. Calkins Eric Yu Hai Chen Jimmy Choi Philippe Conus Cheryl M. Corcoran Barbara A. Cornblatt Covadonga M. Diaz-Caneja Lauren M. Ellman Paolo Fusar-Poli Pablo A. Gaspar Carla Gerber Louise Birkedal Glenthøj Leslie E. Horton Christy Lai Ming Hui Joseph Kambeitz Lana Kambeitz-Ilankovic Matcheri S. Keshavan Sung-Wan Kim Nikolaos Koutsouleris Kerstin Langbein Daniel Mamah Daniel H. Mathalon Vijay A. Mittal Merete Nordentoft Godfrey D. Pearlson Jesus Perez Diana O. Perkins Albert R. Powers Jack Rogers Fred W. Sabb Jason Schiffman Jai L. Shah Steven M. Silverstein Stefan Smesny Walid Yassin William S. Stone Gregory P. Strauss Judy L. Thompson Rachel Upthegrove Swapna Verma Jijun Wang Daniel H. Wolf Phillip Wolff Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Laura M. Rowland Simon D’Alfonso Ofer Pasternak Sylvain Bouix Patrick D. McGorry Rene S. Kahn John M. Kane Carrie E. Bearden Scott W. Woods Martha E. Shenton Barnaby Nelson Justin T. Baker John Torous Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program Schizophrenia |
| title | Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program |
| title_full | Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program |
| title_fullStr | Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program |
| title_full_unstemmed | Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program |
| title_short | Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program |
| title_sort | digital health technologies in the accelerating medicines partnership r schizophrenia program |
| url | https://doi.org/10.1038/s41537-025-00599-w |
| work_keys_str_mv | AT johannatwwigman digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT anneeching digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT yoonhochung digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT habiballahrahimieichi digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT erlendlane digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT carstenlangholm digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT adityavaidyam digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT andrewjinsoobyun digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT anastasiahaidar digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT jessicahartmann digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT angelanunez digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT dominicdwyer digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT adibahamaninasarudin digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT owenborders digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT isabellescott digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT zailyntamayo digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT priyamatneja digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT kangikcho digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT jeanaddington digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT luiskalameda digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT celsoarango digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT nicholasjkbreitborde digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT matthewrbroome digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT kristinscadenhead digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT monicaecalkins digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT ericyuhaichen digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT jimmychoi digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT philippeconus digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT cherylmcorcoran digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT barbaraacornblatt digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT covadongamdiazcaneja digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT laurenmellman digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT paolofusarpoli digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT pabloagaspar digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT carlagerber digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT louisebirkedalglenthøj digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT leslieehorton digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT christylaiminghui digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT josephkambeitz digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT lanakambeitzilankovic digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT matcheriskeshavan digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT sungwankim digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT nikolaoskoutsouleris digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT kerstinlangbein digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT danielmamah digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT danielhmathalon digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT vijayamittal digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT meretenordentoft digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT godfreydpearlson digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT jesusperez digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT dianaoperkins digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT albertrpowers digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT jackrogers digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT fredwsabb digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT jasonschiffman digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT jailshah digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT stevenmsilverstein digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT stefansmesny digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT walidyassin digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT williamsstone digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT gregorypstrauss digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT judylthompson digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT rachelupthegrove digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT swapnaverma digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT jijunwang digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT danielhwolf digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT phillipwolff digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT acceleratingmedicinespartnershipschizophreniaampscz digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT lauramrowland digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT simondalfonso digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT oferpasternak digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT sylvainbouix digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT patrickdmcgorry digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT reneskahn digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT johnmkane digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT carrieebearden digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT scottwwoods digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT marthaeshenton digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT barnabynelson digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT justintbaker digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram AT johntorous digitalhealthtechnologiesintheacceleratingmedicinespartnershipschizophreniaprogram |